Therapeutic Approaches to Obesity
- 226 Downloads
Obesity in the United States has become a public health crisis, with one third of the US population having a body mass index ≥30 kg/m2. Given the profound impact of obesity on cardiovascular disease (CVD), studies of lifestyle modification, pharmacotherapy, and surgical interventions must be reappraised to better define the roles of these approaches in preventing cardiovascular events. Recent clinical trials have attempted to quell the debate over macronutrient composition versus caloric restriction in the dietary approach to weight loss. Our interpretation of these results is that caloric reduction and adherence to diets are of greater consequence than the particular dietary content for weight reduction. For cardiovascular risk factor modification, however, specific macronutrient composition of the diet may have additional impact outside weight loss, although the ultimate relationship between various dietary macronutrients and clinical cardiovascular outcomes is unclear. Although pharmacotherapy has been used for decades to treat obesity, there currently are limited options and recurrent cautionary tales; therefore, we use these agents sparingly. Sibutramine, one of only two medications approved by the US Food and Drug Administration for the long-term treatment of obesity, recently came under intense scrutiny because of a possible increase in cardiovascular events, and it now is contraindicated in patients with established CVD. Orlistat and its over-the-counter form, Alli (GlaxoSmithKline, Research Triangle Park, NC), can induce modest weight loss but frequently are not tolerated because of unpleasant gastrointestinal side effects. Fortunately, there are new medications in phase 3 clinical trials that hold promise as potential alternatives for obesity treatment. Finally, bariatric surgery for morbid obesity refractory to lifestyle interventions has become considerably more common. Surgery can effectively reduce body weight and treat cardiovascular risk factors, particularly diabetes, with acceptable complication rates and should be considered a viable option for appropriate patients. Ongoing clinical trials will clarify the impact of bariatric surgery on cardiovascular events and mortality, as well as the role of surgery as a treatment option that may be considered earlier than currently recommended.
Dr. Khera has been a consultant to Daiichi-Sankyo. No other potential conflicts of interest relevant to this article were reported.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of major importance
- 3.Poirier P, Giles TD, Bray GA, et al.: Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113:898–918.CrossRefPubMedGoogle Scholar
- 10.Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report National Institutes of Health. Obes Res 1998, 6(Suppl 2):51S–209S.Google Scholar
- 17.A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-Agent Constituents for Treatment of Obesity in Adults. Available at http://www.clinicaltrials.gov. Clinical trial #NCT00563368. Accessed December 2009.
- 18.Garvey WT, Troupin B, Tam P, et al.: One-year treatment with low dose VI-0521 in type 2 diabetes demonstrates sustained weight loss and continuous glycemic benefit [abstract]. Obesity 2009, 17:S52.Google Scholar
- 19.Online Pharmacy. Available at htpp://www.drugstore.com. Accessed January 2010.
- 22.Meridia (Sibutramine Hydrochloride): Early Communication About an Ongoing Safety Review. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm191655.htm. Accessed November 2009.
- 23.Meridia (Sibutramine Hydrochloride): Follow-Up to an Early Communication About an Ongoing Safety Review. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198221.htm. Accessed January 2010.
- 24.Padwal R, Li SK, Lau DC: Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003, CD004094.Google Scholar
- 27.Anderson CM, Smith SR, Sanchez M, et al.: Lorcaserin treatment was associated with improvements in cardiovascular risk factors and weight loss in the BLOOM trial [abstract]. Obesity 2009, 17:S52.Google Scholar
- 30.Astrup A: Al Hakim M, Savolainen MJ, et al.: Treatment with liraglutide, a once-daily human GLP-1 analog, for 52 weeks reduces weight and waist circumference: a randomized placebo-controlled trial [abstract]. Obesity 2009, 17:S51.Google Scholar
- 32.Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992, 55:615S–619S.Google Scholar
- 35.Buchwald H, Estok R, Fahrbach K, et al.: Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248–256.e5.Google Scholar
- 40.Long Term Effects of Bariatric Surgery (LABS-2). Available at http://www.clinicaltrials.gov. Clinical trial #NCT00465829. Accessed December 2009.
- 41.National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK): Bariatric Surgery for Severe Obesity. Available at http://win.niddk.nih.gov/publications/gastric.htm. Accessed November 2009.